Fut, nem toborozFázis nélkül
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
A legfontosabb adatok
- Ki végzi
- Hangzhou Endonom Medtech Co., Ltd.
- Hol
- Kína29 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 120 fő vett részt
- Kezdés
- 2020. dec. 25.
- Várható befejezés
- 2026. dec. 25.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- WeFlow-Tbranch Stent Graft System
- A regiszteradat frissítve
- 2024. április 30.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged 18 to 80 years old, no gender limitation
- Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol
- Diagnosed as Stanford type B aortic dissection and needed reconstruction of the left subclavian artery
- The diameter of the proximal anchoring area (the aorta at the posterior edge of the left common carotid artery) range: 18~42mm
- The length of the proximal anchoring area (the distance from the rear edge of the left common carotid artery opening to the first breach) ≥15mm
- The distance between the left common carotid artery and the left subclavian artery ≥5mm
- The distance between the left vertebral artery and the opening of the left subclavian artery is ≥15mm, the diameter of the starting part of the left subclavian artery is 6~20mm
- With proper femoral artery, iliac artery, and brachial artery access, endovascular treatment of the aorta can be performed
Ki nem vehet részt
- Participated in clinical trials of other drugs or devices during the same period
- Contraindications to antiplatelet drugs and anticoagulants
- The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.), and the postoperative drug treatment plan is therefore affected
- Allergic to contrast agents, anesthetics, patches, and delivery materials
- History of myocardial infarction, TIA or cerebral infarction within the past 3 months
- Life expectancy is less than 12 months (such as advanced malignant tumors)
- Acute systemic infection
- Severe liver, kidney, lung, and heart function abnormalities before surgery [Serum creatinine exceeds 2 times the upper limit of normal; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 5 times the upper limit of normal; Serum total bilirubin (STB) more than 2 times the upper limit of normal; Left ventricular ejection fraction is lower than normal by cardiac color Doppler ultrasound examination]
- Pregnant, breastfeeding or cannot contraception during the trial period
- Cannot tolerate anesthesia
- True/false thoracic aortic aneurysm
- Severe stenosis or calcification in the anchoring area at the proximal end of the stent, easily lead to the stent graft difficult adherent
- Investigator judged that not suitable for interventional treatment
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a prospective, multiple center study to evaluate the safety and effectiveness of WeFlow-Tbranch single embedded branch thoracic aorta stent graft system manufactured by EndoNom Medtech (Hangzhou) Co., Ltd.
A vizsgálat csoportja
- WeFlow-Tbranch Stent Graft SystemA vizsgált kezelés
Participants will be treated with WeFlow-Tbranch Stent Graft System
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. április 30.